Jefferies Remains Positive On NUVA, Lowers PT To $34 From $36

Despite near-term challenges and uncertainty in the spine market, Jefferies said that it remains positive on the NuVasive, Inc. (NASDAQNUVA) story and believe the stock should reward long-term investors.

“We rate the shares Buy,” Jefferies writes. “NUVA released preliminary earnings this evening exceeding guidance for 2010 and narrowed 2011 revenue guidance to 10-12% from 10-20%. The company is presenting at an investor conference on Tuesday and should provide further detail.”

Jefferies has lowered its PT on NuVasive to $34 from $36.

NuVasive closed Monday at $26.44.

Read more:


Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Themed By Curio Display Cabinets